Member Info for Pacman121

Snoop aka Dre and also snoop crypto said he'd be back for POC. Obv deramping now for entry.

Not justifiable????? Indian cases up 10 fold since march with between 300k and 350k new cases per day every day last week!! I think anything is justifiable at this point. I'm not sure if that was insensitive or just ridiculous.

GDR wouldn't be working to get into India if it wasn't profitable. Think about the average wage of a test clinician in India against one in the US, and a private one at that. Margin is there. Suggesting entry into a 1.3billion population can't yield a profit is dumb. Divoc seem to like the idea anyway.

Precisely. I wasn't happy with the drop but it does provide new opportunity and if you were happy paying 165p last month then its all good in the 70's. PHE tender really has bolstered this now for anyone with a confidence issue and the FDA are getting through the waiting list quicker and quicker each month this year (understandably given the situation over there).

Good to see the upbeat comments here. All I've seen on the news all weekend is testing testing and also some coverage on more testing. Winning on the tender listing is a beacon for the GDR range and will be picked up on by heath ministries all over the world. Very positive and probably unexpected outcome. No mention of the AIHL (needs to be commercialised first) but thats another massive add just for the UK and a huge one for once launched in the US. Mortgage killer stock in the making here. AVCT has been promising the world for a year and short of buying new houses for directors it really has a long way to go to justify its market cap. We are already justified with several tests ready to go, some of which took years of R&D. Sales need to come and they will Todays RNS just took what was left of the risk out of this stock for me.

15000 added at 72.5p and happy with the the small premium to Friday as its all coming together. Traction will get hold very short term now I think as my position reflects. Many under water will be averaging down and the SP starts to move. For some reason many feel more comfortable adding as the SP climbs rather than when its screaming at the lows. Each to their own risk management.

Thermo Fisher Scientific, TaqPath™ COVID 19 High Throughput Combo Kit (also called "The Amplitude™ Solution with the TaqPath™ COVID 19 High Throughput Combo Kit") is still shown as not FDA authorised on the FDA site which hasnt been updated since the 5th April yet we know it has as per below: https://www.fda.gov/media/145928/download

That is the same one isn't it?

They were notified of this yesterday and haven't made any changes so lets see.

Lots of useful information deleted by Admin. That's not cricket as far as I'm concerned. Obv one individual disrupting the entire board excessively making it impossible for considered debate.

ahahahahaha. This thread is absolutely brilliant.

@maestro

Look again mate. There's a lot more than 1 PCR kit that's been issued EUA. It's hard to keep up with you but here is the link for others. Also if you spend time and really go into the detail GDR's is better than most. But you will need to look into each test individually to see this.

https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/notifications-and-emergency-use-authorizations-faqs-testing-sars-cov-2

Hadn't spotted it. Thanks.

Did someone just report my last post? It's gone :/ 11.50? Anyone see it? Admin can you put it back up please.

I considered that and would agree if it was this time last year but the distribution agreement came to play at the end of Jan this year when all that was fairly transparent. I don't mean this sarcastically but if someone like mastero (PI/trader whatever) can pick up on number of PCR tests etc being signed off this year then surely the team at Beckman will have that accounted for in its plan.

To counter your second point I agree £400k would not be much to BC, but you have to look at the other resources they are putting up, screening calls, training lab staff, storing the stock, taking calls, emails, pairing enquiriers with staff to customers to explain chemistry etc also adds up quickly and if they are not making money here then they will be losing it somewhere else and the resource could have been better used else where if that makes sense.

Have happily sought to distribute without FDA already aware of the delays and will know about the FDA process better than anyone here. They are top in their game which poses 2 questions:

1. Would they actively seek a distribution deal without leads after 6 months of prior collaboration?
2. Have Beckman Coulter ever launched a non-profitable product? (I can't find an example)

Genedrive market cap really is tiny given the number of products at advanced developemnt and calibre.

26 out of 91. It's on the FDA website against companies that have filed for EUA use. A lot of shoddy reagent types on there. Think the norm is going away from reagents as they are more error prone which is good for us. List was updated yesterday. Seem to be getting through them now.

You're describing a buy on rumour sell on news thing. Once money starts piling in the company's market cap is underlined by cash and the company increases in value. If we are selling globally then value will out.

If there was a leak of bad news it would of tanked today. I'd say the drop today and yesterday was caused by cautious/nervous retail who also caused the rise on Monday following some fairly upbeat posts. Remember Beckman Coulter are already selling 23m Antigen and 30m Antibody tests a month. GDR is it's only PCR offering. 7m tests covers our entire market cap and works out just over 10% of a months tests currently sold by BC! Given PCR is a more accurate test, very plausible that existing BC customers may have switched to the PCR test depending on their application, plus those that have been waiting since the collaboration started in August, then any new business on top of that. The initial take up could have been quite high given the pent up period. We'll find out tomorrow. DOD contracts for a test the DOD actuallly financed GDR to design and produce as well as the HCV test and Antibiotic induced hearing loss test due out this summer are all mile stone drivers to give us a nice sustained rise. Too many stuck in the past. Guess we will all be put straight tomorrow. Hope your positions go well.

These tests work out at near £15 or $25. The key points for US users are that B+C is a well-established US company. Labs (mostly private) are paid high reimbursement rates for doing a test - $120 = 450% . Higher rates remove pricing pressure on suppliers because US is a private healthcare market = Labs and Doctors can move faster and make own decisions (no lengthy tenders). Also there is still a huge testing shortfall in the US (more efficient methods/systems demanded).

All this info is public. Def worth reading some of it before pressing sell/buy. Understanding the product is a key part of investing, of course most here aren't that.

It remains on sale. It's just now like every other product on the site which requires you to make contact to complete a purchase. Could be for a number of reasons, but given they were available up until yesterday it would suggest they are curbing demand while they bring in more stock. It could also be an upsell thing. The market has been aware of the test coming to market for 6 months, hence my view, but thats all it is.

Test are being confused. GDR's is a revolutanry one that uses a “ready-to-go” solid PCR bead format that eliminates the need for time-consuming and error-prone reagent preparation, a requirement in all other open-platform tests. The Antigen tests mentioned on this thread were launched in December. GDR's is a different market completely. I think people are trying to undermine Beckman Coulters expertise in the field. They wouldn't launch GDR's test 2 months after launching an Antigen test after being in a collaboration for 6 months and then set a price users in the field would not be willing to pay.

Also Genedrive created a the one-step CE-IVD PCR Kit to address the need for high-volume throughput testing following the The World Health Organization recommendation to use respiratory samples with a RT-PCR test for SARS-CoV-2 testing.

What excites me is that after a couple of months BC are selling 25+ milion antigen tests and a similiar amount of antibody tests already! Talk about having your name back up what you're selling! Lots of info on the site.